Vietnam

AI Citation Summary

• Country: Vietnam
• Product line: Medical devices
• Regulator / source: Primary regulator - Ministry of Health (MOH); device-specific review historically under the Department of Medical Equipment and Health Works (DMEC/DMEHW); drug-adjacent coordination through DAV (Drug Administration of Vietnam) — exact current institutional split unconfirmed this round, see Regulatory Authority section
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Medical devices sold in Vietnam are regulated by the Ministry of Health (MOH — Bộ Y tế), with device-specific technical review historically carried out by the Department of Medical Equipment and Health Works (DMEC/DMEHW — Vụ Trang thiết bị và Công trình y tế) and drug-adjacent coordination through DAV (Drug Administration of Vietnam — Cục Quản lý Dược), under Decree No. 98/2021/ND-CP on Medical Device Management, as amended by Decree No. 07/2023/ND-CP (effective March 3, 2023) and subsequent implementing circulars — Vietnam's device-authority naming has shifted more than once since the 2021 reform, so confirm the current institutional split between DAV and DMEC directly with MOH before a submission-critical filing. Devices are sorted into four ASEAN-aligned risk types (Type A, lowest risk, through Type D, highest risk): Type A goes through a simplified notification/declaration (khai báo), while Type B, C, and D require a full marketing-authorization registration (đăng ký lưu hành) that in practice also requires a Vietnam-based authorized representative, a notarized/authenticated foreign-document chain, and — for Type C/D — local Vietnamese technical testing. Official review targets range from 5–10 working days for a Type A notification up to 90 working days for a Type D marketing authorization, but realistic elapsed time runs far longer once notarization/authentication lead time, testing-lab queues, and supplementary-information rounds are factored in — commonly 2–6 weeks for Type A, 9–18 months for Type B, and 18–36+ months for Type C/D.
• Key fees: Market characteristics: Market size approximately USD 2.0 billion in 2023, growing roughly 10% annually. Import dependence is very high (approximately 75%), with Germany, Japan, and the United States as the primary import sources; domestic manufacturers have made inroads in basic equipment but remain limited overall. Vietnam's rapid economic growth is driving increasing demand for premium private healthcare.
• Local requirement: Medical devices sold in Vietnam are regulated by the Ministry of Health (MOH — Bộ Y tế), with device-specific technical review historically carried out by the Department of Medical Equipment and Health Works (DMEC/DMEHW — Vụ Trang thiết bị và Công trình y tế) and drug-adjacent coordination through DAV (Drug Administration of Vietnam — Cục Quản lý Dược), under Decree No. 98/2021/ND-CP on Medical Device Management, as amended by Decree No. 07/2023/ND-CP (effective March 3, 2023) and subsequent implementing circulars — Vietnam's device-authority naming has shifted more than once since the 2021 reform, so confirm the current institutional split between DAV and DMEC directly with MOH before a submission-critical filing. Devices are sorted into four ASEAN-aligned risk types (Type A, lowest risk, through Type D, highest risk): Type A goes through a simplified notification/declaration (khai báo), while Type B, C, and D require a full marketing-authorization registration (đăng ký lưu hành) that in practice also requires a Vietnam-based authorized representative, a notarized/authenticated foreign-document chain, and — for Type C/D — local Vietnamese technical testing. Official review targets range from 5–10 working days for a Type A notification up to 90 working days for a Type D marketing authorization, but realistic elapsed time runs far longer once notarization/authentication lead time, testing-lab queues, and supplementary-information rounds are factored in — commonly 2–6 weeks for Type A, 9–18 months for Type B, and 18–36+ months for Type C/D.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Direct Answer

Medical devices sold in Vietnam are regulated by the Ministry of Health (MOH — Bộ Y tế), with device-specific technical review historically carried out by the Department of Medical Equipment and Health Works (DMEC/DMEHW — Vụ Trang thiết bị và Công trình y tế) and drug-adjacent coordination through DAV (Drug Administration of Vietnam — Cục Quản lý Dược), under Decree No. 98/2021/ND-CP on Medical Device Management, as amended by Decree No. 07/2023/ND-CP (effective March 3, 2023) and subsequent implementing circulars — Vietnam's device-authority naming has shifted more than once since the 2021 reform, so confirm the current institutional split between DAV and DMEC directly with MOH before a submission-critical filing. Devices are sorted into four ASEAN-aligned risk types (Type A, lowest risk, through Type D, highest risk): Type A goes through a simplified notification/declaration (khai báo), while Type B, C, and D require a full marketing-authorization registration (đăng ký lưu hành) that in practice also requires a Vietnam-based authorized representative, a notarized/authenticated foreign-document chain, and — for Type C/D — local Vietnamese technical testing. Official review targets range from 5–10 working days for a Type A notification up to 90 working days for a Type D marketing authorization, but realistic elapsed time runs far longer once notarization/authentication lead time, testing-lab queues, and supplementary-information rounds are factored in — commonly 2–6 weeks for Type A, 9–18 months for Type B, and 18–36+ months for Type C/D.

Quick Reference

Market Overview

• Population: Approximately 99 million (2024); median age approximately 31 years; rapidly urbanizing, with healthcare demand concentrated in Hanoi (north) and Ho Chi Minh City (south).
• Healthcare system: Universal health insurance (BHYT — Bảo hiểm y tế) covers approximately 93% of the population, though reimbursement levels remain limited. Public hospitals dominate (approximately 85% of healthcare resources); private hospitals are growing rapidly, led by groups such as Vinmec, FV Hospital, and Hoan My.
• Market characteristics: Market size approximately USD 2.0 billion in 2023, growing roughly 10% annually. Import dependence is very high (approximately 75%), with Germany, Japan, and the United States as the primary import sources; domestic manufacturers have made inroads in basic equipment but remain limited overall. Vietnam's rapid economic growth is driving increasing demand for premium private healthcare.
• Regulatory maturity: Low to moderate, with rapid recent development but notable instability at the implementation level. Review capacity is still developing, the post-COVID backlog (2020–2022) has not been fully cleared as of this verification round, and the regulatory framework references ASEAN/IMDRF norms while remaining substantially localized — notarization/authentication requirements and mandatory local technical testing for Type C/D devices have no close equivalent among Vietnam's ASEAN neighbors.

Market-Entry Logic

Vietnam medical-device entry should be separated into MOH/DAV/DMEC regulatory classification and review, local authorized-representative appointment, document authentication chain, technical dossier and Vietnamese-language translation, local technical testing (Type C/D), import, post-market surveillance, and public procurement/private-hospital channel access. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private-hospital adoption, distributor coverage, installation/training, service uptime, tenders, and reimbursement coding.

Main Players and Channel Map

Development Trends

1. Approval and access are increasingly separate: technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
2. Local execution quality is a major differentiator: strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk in a system where documentation quality — more than the nominal device type — drives real elapsed time.
3. Evidence expectations are rising: payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data alongside the regulatory dossier.
4. Institutional naming and fee structures have been reported to be in flux (2024–2026): secondary regulatory-services sources describe further amending decrees, circulars, and a possible portal/agency-name transition beyond Decree 07/2023, and at least one source claims a temporary fee reduction is in effect. None of these specific claims could be independently corroborated against a primary DAV/MOH source this round (see Element 3 and Element 5 verification notes) — treat them as directional signals, not confirmed facts, until checked directly with MOH.
5. Partner control should be managed early: contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights before signing, not after a dispute.

Regulatory Authority and Legal Framework

• Competent authority: Ministry of Health (MOH — Bộ Y tế). Device-specific technical review has historically sat with the Department of Medical Equipment and Health Works (DMEC/DMEHW — Vụ Trang thiết bị và Công trình y tế); drug-adjacent and some device functions have also been described as consolidated under DAV (Drug Administration of Vietnam — Cục Quản lý Dược) following a 2023 institutional reform. This page could not independently confirm the current institutional split during this verification round — direct fetches of dav.gov.vn and dmec.moh.gov.vn both failed (connection reset and DNS resolution failure respectively) — confirm the correct submitting authority with a local representative or directly with MOH before filing.
• Official portals: https://dav.gov.vn (unreachable to direct fetch this round); Medical device registration system: https://dichvucong.moh.gov.vn (MOH Public Services Portal).
• Governing regulations:
  • Decree No. 98/2021/ND-CP on Medical Device Management (effective January 1, 2022; supersedes Decree 36/2016) — the master framework for classification, registration, import, and post-market obligations.
  • Decree No. 07/2023/ND-CP (effective March 3, 2023) — amends Decree 98/2021, principally by extending transition/grandfathering deadlines for classification results and import licenses issued under the prior regime, addressing the post-COVID review backlog. Cross-referenced across secondary regulatory-services sources; treat any further specific provision beyond the extension purpose as unconfirmed until checked against the primary text.
  • Circular No. 05/2022/TT-BYT — implementing regulations for Decree 98/2021.
  • Medical Device Classification Guidelines (Circular).
  • Decree 111/2021/ND-CP — Vietnam's Labeling Law, the operative rulebook for mandatory Vietnamese-language labelling.
  • Historical reference: Decree 36/2016/NĐ-CP (superseded), Circular 30/2015 (updated).
  • 【待核验】Secondary regulatory-services sources this round separately reference further 2024–2026 amending instruments (an additional amending decree, new procedural circulars, and a possible agency-portal rename) — none could be corroborated against a primary source or a second independent authoritative source and are therefore not cited by specific number on this page; confirm the current regulation set directly with DAV/MOH/DMEC before submission.

Element 1 — Device Classification and Pathway Branching

Classification is the decision that determines whether a device needs local Vietnamese technical testing, how much documentation is required, and which of the two legal instruments — notification or registration — applies. Vietnam's four-type system tracks the ASEAN Medical Device Directive (AMDD)/GHTF risk model; classification requests can be submitted to DAV/DMEC for a formal determination (approximately 4–8 weeks).

Pathway Branching Table — Route by Type and Evidence

Branching logic in practice: classification alone decides whether the device needs only a notification (Type A) or a full marketing-authorization registration (Type B/C/D); for Type C/D, classification additionally decides whether local Vietnamese technical testing is required. Existing CE/FDA evidence does not create a separate procedural track the way Malaysia's Verification Route or Singapore's Abridged Route do — it operates inside the same DAV/DMEC review, reducing supplementary-information rounds rather than replacing the review itself.

Element 2 — License-Holder Logic: The Authorized Representative Is a Decision-Grade Choice

Vietnam sits squarely in the Southeast Asia region's dominant "Mode B" pattern — mandatory local licence-holding — the same structural logic that applies in Indonesia, Thailand, Malaysia, and the Philippines, and the opposite of Singapore's foreign-friendly exception. A foreign manufacturer cannot register a device directly with DAV/DMEC under any route. A legally established Vietnamese entity with import qualifications, acting as the Authorized Representative (AR), must submit the application, and the marketing-authorization certificate (số đăng ký lưu hành) is typically issued in the AR's name, with the foreign manufacturer listed as the manufacturer of record.

• The AR typically holds the certificate itself, not merely files on the manufacturer's behalf — the single most consequential fact for a manufacturer negotiating a Vietnamese distribution agreement, since it puts certificate control, MOH portal account access, and variation-application authority in the AR's hands by default.
• AR qualification requirements: an MOH-issued medical device business licence (Giấy phép kinh doanh thiết bị y tế) covering import activities; a quality-management-system in place (ISO 9001 or equivalent, requirements vary by risk type); and demonstrated adverse-event reporting and product-recall capability.
• Changing representatives requires a certificate variation application — a cumbersome, non-trivial process — so contractual provisions for technical-data-package ownership and transition arrangements must be established from the outset, not after a partner dispute.

Structuring Options

• What happens when a distributor relationship ends: because the AR is typically also the certificate holder, changing commercial partners when the distributor itself is the AR generally requires a formal registration-variation application to DAV/DMEC, which can interrupt supply during the transition. An independent third-party AR structure avoids this specific risk by keeping the certificate outside the commercial distribution relationship entirely — a documented benefit cited by regulatory-services specialists specifically for the Vietnamese market.
• Recommended AR selection criteria: (1) a documented track record of successful DAV/DMEC applications for similar product categories; (2) in-house Vietnamese technical-document translation capability; (3) dedicated registration staff; (4) no representation of directly competing products. The Vietnamese distributor/AR market is reasonably concentrated, with professional medical-device representatives based in both Ho Chi Minh City and Hanoi.

Element 3 — Registration Validity and Review-Timeline Ranges

On the "indefinite validity" question — verified carefully, not confirmed: the CONTENT-SKELETON brief for this page flagged a specific question — whether Vietnam moved from 5-year registration validity to indefinite validity under a later amendment to Decree 98/2021. During this verification round, one secondary regulatory-services source (meddeviceguide.com) claimed the registration number now carries "indefinite validity" as part of a broader set of claims (a named agency "IMDA," a specific "Consolidated Decree 98 (March 2026)," new circular numbers, and China's NMPA listed as a recognized reference country). A second secondary source (pureglobal.com) independently used a similar unverifiable agency name ("IMDA/VIMDA") and referenced the same unconfirmed 50%-fee-reduction claim, which is a pattern consistent with templated or low-confidence content rather than two genuinely independent confirmations. Neither source could be cross-checked against DAV/MOH primary pages (both returned connection errors to direct fetch this round), and the NMPA-recognition claim directly contradicts the cross-verified regional pattern — documented on this site's Southeast Asia market-entry topic page and corroborated across the Malaysia and Thailand pages — that no ASEAN regulator reviewed on this site recognizes NMPA as a reference market. This page therefore keeps the 5-year validity figure as the operative fact, consistent with the Southeast Asia market-entry topic module, and flags the indefinite-validity claim as 【待核验】rather than incorporating it — confirm directly with DAV/MOH before relying on either figure for a submission-critical filing or a renewal-budget decision.

Why the timeline range is wide: as on comparable ASEAN pages, documentation quality and supplementary-information rounds — not the type letter alone — are the strongest predictor of real elapsed time. Vietnam's notarization/authentication chain and local-testing-lab queue add two Vietnam-specific delay sources that most neighboring markets do not carry at the same intensity.

Element 4 — Authorized Representative In-Country Obligations

Holding a registration is not a one-time event. The AR carries ongoing, non-transferable duties for as long as the product remains on the Vietnamese market.

Practically, appointing an AR does not remove these duties from the manufacturer's planning — it only determines who legally carries them. A manufacturer relying on an independent third-party AR should still confirm, contractually, who resources vigilance reporting, testing-lab coordination, and complaint handling day-to-day.

Element 5 — Fee Model: Government Fees, AR/Translation/Testing Costs, and Renewal

Vietnam mixes modest one-time government application fees with materially larger AR service, translation, authentication, and local-testing costs — the government fee is a small fraction of total project cost, unlike some markets where the government fee itself is the dominant line item.

On the "50% fee discount" claim — flagged, not incorporated: two lower-confidence secondary sources referenced this round both mention a temporary 50% reduction in MOH application fees said to run through the end of 2026, alongside other unconfirmed claims (a specific new agency name, new circular numbers). This page does not incorporate the discounted figures because neither source could be independently corroborated and both show signs of templated/low-confidence content (see Element 3) — confirm the current, live fee schedule directly with DAV/MOH or a local AR before budgeting a submission.

Practical note: because government fees are small relative to AR, translation, authentication, and testing costs, the total project cost of a Vietnamese registration is driven far more by dossier quality, AR selection, and how many supplementary-information rounds occur than by the class/type number alone.

Element 6 — Registration Forms: Notification vs. Marketing Authorization

A structural note worth stating plainly: unlike Malaysia, which treats every risk class as a form of "Registration" differing only in whether CAB review applies, Vietnam uses two genuinely different legal instruments — notification for Type A and marketing-authorization registration for Type B/C/D — with the registration route additionally splitting by whether local technical testing is required (Type B generally not; Type C/D generally yes).

Element 7 — Special Requirements

Labelling — Vietnamese Is Mandatory, No Exceptions

Vietnam's labelling rulebook is Decree 111/2021/ND-CP. Product packaging must carry Vietnamese-language labelling including: product name (in Vietnamese), model number, manufacturer, importer, registration number, date of manufacture, expiry date, and usage instructions — all in Vietnamese. Vietnamese-language Instructions for Use (Hướng dẫn sử dụng) are also mandatory. This is a structurally heavier regime than Malaysia (English or Bahasa Malaysia accepted) or Singapore/Philippines (English accepted), placing Vietnam alongside Thailand and Indonesia in the group of ASEAN markets with a mandatory local-language requirement. Translation quality is the most frequently cited trigger for supplementary-information requests — commission a professional Vietnamese medical-device translation provider, not a generalist translator.

Notarization/Authentication Chain — Vietnam's Most Distinctive Administrative Challenge

• For documents from Hague Apostille Convention member countries: Apostille authentication (available since Vietnam joined the Convention in 2023) → Vietnamese Ministry of Foreign Affairs or provincial judicial-department authentication → certified Vietnamese translation.
• For documents from non-Hague-Convention countries: notarization in the country of origin → authentication by the Vietnamese Embassy/Consulate in that country → Vietnamese Ministry of Foreign Affairs authentication.
• The chain is time-consuming (2–4 months) and should be set as a separate project milestone, run in parallel with technical-dossier preparation rather than after it — this is the most common source of avoidable delay reported for Vietnam specifically.
• Authenticated-document expiry risk: notarized/authenticated documents typically carry a 6–12 month validity window. Given DAV/DMEC's review backlog, a prolonged review can cause documents to expire mid-review, forcing costly and time-consuming re-authentication — build expiry tracking into the project plan from day one.

Local Vietnamese Technical Testing (Type C/D)

Type C/D products generally require technical verification testing at a MOH-designated Vietnamese testing facility (e.g., a national medical-device quality-control center), covering electrical safety, EMC, and biocompatibility-related performance parameters, tested against TCVN (Vietnamese National Standard) series that are largely — but not always exactly — equivalent to IEC/ISO standards. This requirement is not waived by an existing CE or FDA approval; even a device with strong reference-market evidence must still complete local testing if its Type falls in the required band, and testing-lab scheduling queues (commonly 3–9 months) mean this should be booked at the same time the DAV/DMEC application is submitted, not after.

UDI — Not Yet Mandatory

Vietnam has not yet established a mandatory Unique Device Identification (UDI) system. UDI is referenced in the regulatory reform agenda but was not enforced as of this verification round — a lighter position than Singapore, which has required UDI for high-risk devices since 2021.

Element 8 — Shortcut Pathways: Reference-Country Leverage, ASEAN CSDT, and What Vietnam Does NOT Offer

Vietnam's search-demand profile for expedited/accelerated registration is one of the strongest reasons to be precise here: Vietnam does not operate a formal, procedurally separate fast-track tied to CE or FDA approval, unlike Malaysia's Verification Route, Thailand's Expedited Review, or Singapore's Abridged/Immediate routes. What Vietnam does offer is functionally narrower but still consequential — reference-country evidence is treated as close to a prerequisite, not merely an accelerant, for Type B/C/D dossiers.

Quick Assessment

What Reference-Country Evidence Does — and Does NOT — Waive

• Reduces deficiency/supplementary-information queries for Type B/C/D, particularly when the CE certificate or FDA clearance/approval is submitted with a complete technical summary rather than the decision letter alone.
• FDA PMA clinical data can substitute for locally generated clinical evidence on Type D devices — the most valuable specific effect identified in this page's sources.
• Does NOT waive the Vietnamese AR requirement.
• Does NOT waive mandatory Vietnamese-language labelling.
• Does NOT waive local Vietnamese technical testing for Type C/D — some Type C/D products still require the local test report even with a strong CE or FDA file; confirm testing scope for the specific product category early.
• Does NOT create a separate, faster procedural track — it is evidence within the standard review, not a bypass of it.
• Does NOT extend to NMPA — Chinese manufacturers without CE or FDA approval should treat obtaining CE as close to a market-entry prerequisite for Vietnam.

On "Decree 98 Article 30" and Successor Provisions

The CONTENT-SKELETON brief for this page asked whether a specific mechanism — commonly referenced informally as sitting within Decree 98/2021's dossier-evidence provisions — grants reduced-dossier or expedited treatment to reference-regulator-approved devices, and whether a specific article number (e.g., Article 30) or a successor decree governs it. This page was not able to directly access the primary Vietnamese-language decree text during this verification round (the Vietnamese legal-database source thuvienphapluat.vn returned an access-denied response, and DAV/MOH's own portals were unreachable to direct fetch). The functional mechanism described above — overseas-registration proof as a dossier-evidence requirement, not a separate fast-track — is corroborated across multiple independently reviewed secondary regulatory-services sources and is consistent with this site's Southeast Asia market-entry topic module. The exact article/provision number is marked 【待核验】; confirm it directly with DAV/MOH or a Vietnam-licensed regulatory counsel before citing it in a formal submission.

Practical Recommendations

• Treat CE (or FDA) as a practical prerequisite, not an optional accelerant, for any Type B/C/D Vietnam filing — if the device has neither, budget time to obtain one before targeting Vietnam.
• Submit FDA evidence with the full 510(k) or PMA Summary, not the decision letter alone, since this materially affects how much the deficiency-query reduction actually delivers — most valuable for Type D devices seeking to substitute PMA clinical data for local evidence.
• Do not assume CE/FDA evidence removes local Type C/D technical testing — confirm the specific product category's testing requirement with DAV/DMEC or the local AR early in the project.
• Build one ASEAN CSDT-format dossier and reuse it across Vietnam, Malaysia, Thailand, and the Philippines filings to reduce incremental dossier-preparation cost, while still budgeting Vietnam-specific translation, authentication, and local-testing workstreams separately.
• Do not expect a Malaysia/Thailand/Singapore-style formal fast-track to appear in Vietnam — the realistic lever on speed is documentation quality, early testing-lab and authentication-chain scheduling, and reference-country evidence quality, not a procedural shortcut.

IVD-Specific Requirements

• Classification framework: IVD products follow a separate classification scheme based on the WHO IVD classification framework, structurally distinct from the general Type A–D device scheme used for hardware, though it maps onto the same underlying low-to-high risk logic.
• Registration mechanics: IVDs follow the same two-instrument structure as general devices — lower-risk IVDs proceed via notification, higher-risk IVDs via marketing-authorization registration — submitted through the same MOH Public Services Portal.
• Local testing exposure: Vietnam's Type C/D local-technical-testing requirement (electrical safety, EMC, and biocompatibility-related parameters) is documented for general devices in the sources reviewed this round; whether specific high-risk IVD categories (e.g., HIV/HBV/HCV screening assays, the categories that carry mandatory local-testing requirements in neighboring Thailand) carry an equivalent or distinct local-testing or local-validation requirement in Vietnam could not be independently confirmed this round — 【待核验】, and should be confirmed directly with DAV/DMEC or a local regulatory partner before committing to an IVD registration timeline.
• Reference-country evidence for IVDs: CE IVDR and FDA IVD clearances are accepted as overseas-registration proof on the same basis as general-device CE/FDA evidence (Element 8), reducing deficiency-query volume, though — as with general devices — this does not constitute a formal fast-track.
• Vietnamese labelling applies equally to IVDs: product name, intended use, manufacturer, importer, registration number, and usage instructions must all appear in Vietnamese on IVD kit labelling and package inserts.
• Clinical/performance evidence: required for Type C/D IVDs; a literature-based performance-evidence summary is generally acceptable where the intended use and risk profile support it, consistent with the general-device clinical-evidence standard.

SaMD and Digital Health Medical Device Software Requirements

• Regulatory status: software qualifies as a medical device in Vietnam when its intended purpose matches the medical-device definition under Decree 98/2021 — diagnosis, monitoring, treatment support, or disease prevention/alleviation — and is regulated through the same Type A–D classification and notification/registration structure as hardware devices; Vietnam does not currently operate a separate SaMD-specific decree or a distinct SaMD class scheme comparable to Thailand's IMDRF-aligned SaMD/AI guidance.
• Classification: SaMD is classified against the same general risk factors (intended use, clinical consequence of an incorrect or delayed output) used for hardware devices; most clinical decision-support and diagnostic-assist software should be expected to land in Type B or C pending a formal classification determination, rather than assuming Type A treatment by default.
• Documentation: software documentation aligned to IEC 62304 is called out explicitly in the technical-dossier requirements for SaMD and connected devices, alongside the standard risk-management summary (ISO 14971) and, for Type C/D, clinical evidence.
• AR and local-testing requirements are unchanged for software: a SaMD product still needs a Vietnamese AR holding a valid business licence, and Type C/D software should be assumed to carry the same local-technical-testing exposure as hardware unless a classification determination confirms otherwise — confirm testing scope (which for pure software may be scoped differently than physical electrical-safety/EMC testing) directly with DAV/DMEC.
• Vietnamese-language requirement applies to software UI and documentation: labelling and Instructions for Use requirements extend to software product descriptions and user-facing documentation, not only physical packaging.
• Practical implication: a SaMD product already classified and cleared in the EU or US should be reassessed against Vietnam's own Type A–D classification logic rather than assumed to inherit the EU/US risk class directly, and should budget for IEC 62304-aligned documentation from the outset rather than retrofitting it late in the dossier-preparation process.

Expedited Market Access — What Actually Speeds Up a Vietnam Filing

Because expedited/accelerated-registration search demand for Vietnam sits just outside page-one visibility, the operative facts matter more than the marketing label "fast track." Vietnam has no formal expedited-review or reliance route comparable to Malaysia's Verification Route, Thailand's Expedited Review, or Singapore's Abridged/Immediate routes — this is the single most important fact to set expectations correctly before budgeting a launch timeline.

1. There is no procedural shortcut to unlock — plan around the standard track. Do not build a commercial launch plan assuming a Vietnam-specific fast-track exists; none was identified in the primary or cross-checked secondary sources reviewed this round, and Vietnam's own topic-comparison position on this site explicitly notes the absence of a formal CE/FDA-linked fast track shared by Thailand and Indonesia.
2. Reference-country evidence is the biggest lever you actually control. A complete CE certificate or FDA 510(k)/PMA Summary (not the decision letter alone) submitted with the initial dossier materially reduces supplementary-information rounds — and each avoided round saves 3–6 months in practice, which compounds faster than any procedural workaround would.
3. Start the notarization/authentication chain and local-testing booking on day one, not after dossier drafting. These two Vietnam-specific workstreams — each running 2–9 months independently — are the most common reasons a "should be 12 months" project runs to 24, and neither is compressible by reference-country evidence.
4. Sequence Type B ahead of Type C/D where the product line allows it. A manufacturer with both a lower-risk and a higher-risk product in the same family can reach the Vietnamese market with the Type B product in roughly a third of the time a Type D product needs, generating early revenue and local-market experience before the higher-risk registration completes.
5. Track authenticated-document expiry against the realistic (not official) timeline. Because authenticated documents run 6–12 months and Type C/D reviews commonly run 12–36 months, plan for at least one re-authentication cycle on longer projects rather than treating the authentication chain as a one-time cost.
6. Treat any claim of a Vietnam-specific 2025–2026 fast-track or fee discount as unverified until confirmed with DAV/MOH. This page identified secondary-source claims of a faster review window and a temporary fee reduction during this verification round that could not be corroborated against a primary source and showed signs of low-confidence/templated content (see Element 3 and Element 5) — do not build a project timeline or budget around an unconfirmed claim.
7. Documentation quality remains the largest lever you control, exactly as on comparable ASEAN pages. Independent case patterns across the region show deficiency-round count as the single biggest swing factor in actual elapsed time; investing in a complete, correctly translated, TCVN-aware dossier on the first submission consistently outperforms chasing a shortcut that does not exist in Vietnam's current system.

Registration Dossier Requirements

• Administrative documents (notarization + authentication required):
  • Registration application form (MOH prescribed format)
  • Vietnamese representative's business licence and operating permit
  • Foreign manufacturer's authorization letter (notarized + Vietnamese consular authentication or Apostille)
  • Foreign manufacturer's Free Sale Certificate (FSC), notarized and authenticated, specifying Vietnam as the destination country or a global FSC
  • Foreign manufacturer's GMP certificate/manufacturing licence, notarized and authenticated
  • CE certificate / FDA approval / other recognized market-approval documents where available — see Element 8
• Technical documents (Vietnamese translation required):
  • Product description, intended use, and technical specifications
  • Performance and safety test reports (IEC/ISO standards; some products require evidence of compliance with the Vietnamese-equivalent TCVN standard)
  • Risk-management summary (ISO 14971)
  • Clinical evidence (required for Type C/D; literature review is generally acceptable)
  • Software documentation (IEC 62304 for SaMD, where applicable)
• Local Vietnamese technical test report (required for Type C/D): issued by a MOH-designated Vietnamese technical-testing facility, covering electrical safety, EMC, and biocompatibility-related performance parameters.
• Labelling and IFU (Vietnamese mandatory): Vietnamese-language product label (Nhãn sản phẩm) and Instructions for Use (Hướng dẫn sử dụng), compliant with Decree 111/2021/ND-CP.

Post-Market Surveillance, Adverse Event Reporting, and Recalls

• Adverse-event reporting: death or serious health deterioration must be reported to DAV/the provincial health authority within 15 calendar days; the AR is the primary reporting-responsible party, submitting via the MOH Public Services Portal or the relevant provincial health-authority window.
• Recall rules: recalls must be reported to DAV and relevant provincial health authorities, and recall notices must be published through official Vietnamese media channels.
• Post-market surveillance system: Decree 98/2021 requires PMS for marketed products; the AR must submit annual safety-surveillance reports — a continuing obligation, not a one-time submission requirement.
• Inspections and audits: MOH/DAV may conduct post-market inspections of the AR, reviewing product-quality records and adverse-event-reporting practice.
• Registration renewal management: the AR is responsible for timely renewal of the 5-year marketing-authorization certificate; a lapse can suspend market access, and given DAV/DMEC's processing delays, filing 15–18 months ahead of expiry is the practically recommended lead time.

Import and Customs Requirements

• Import authorization: products may clear customs upon obtaining a valid marketing-authorization certificate (số đăng ký); importers must hold a business licence (GP kinh doanh).
• Customs requirements: HS-code declaration required (Vietnam uses the AHTN coding system); the marketing-authorization number must be declared at customs.
• Type C/D import permit: some high-risk products require a per-shipment import permit (Giấy phép nhập khẩu) issued by MOH; approval takes approximately 2–4 weeks per application and should be planned for in advance, particularly for the first shipment after registration.
• Labelling at import: Vietnamese-language labelling meeting Decree 111/2021/ND-CP must be in place at the point of market entry, including product name, model number, manufacturer, importer, registration number, manufacture/expiry dates, and Vietnamese-language usage instructions.

Market Access Channels

Registration is the compliance entry point, not the commercial one — DAV/MOH approval does not equal hospital procurement or reimbursement access.

• Public hospitals (primary channel): Vietnamese public hospitals procure through provincial/central government tender processes (đấu thầu); products must be included in the MOH unified procurement catalogue (Danh mục thiết bị y tế) to be eligible; price competition is intense and tender procedures are complex, but this channel represents the largest procurement volume (approximately 70%).
• Private premium hospitals/clinics: Premium private hospitals in Ho Chi Minh City and Hanoi (Vinmec, FV Hospital, and others) are the preferred entry channel for imported premium devices, with relatively flexible procurement decisions compared with the public-tender process.
• Distributor networks: Vietnamese medical-device distribution is highly dependent on local distributor networks — Hanoi-based regional distributors, Ho Chi Minh City-based regional distributors, and provincial distributors; direct sales without a distribution partner are extremely difficult to operate.
• Government procurement framework (Catalog List): some devices must be included in the MOH unified procurement catalogue to be eligible for public-hospital purchase, a separate commercial gate beyond the marketing-authorization certificate itself.

Market Entry Strategy and Key Risks

Recommended approach:

• Decide the AR structure deliberately, not by default (Element 2) — because the AR typically holds the certificate itself, treat "use our distributor as AR" as one option among three, not the automatic choice.
• Prioritize obtaining CE or FDA approval before targeting Vietnam for Type B/C/D products, and present it as core reference evidence in the Vietnamese submission — this is close to a practical prerequisite, not simply a bonus, and is the single biggest lever a manufacturer controls on deficiency-round count.
• Use Ho Chi Minh City (south) as the initial entry point — southern private hospitals are relatively more open to new-product adoption; northern public hospitals in Hanoi have larger budgets but more complex, more competitive tender processes, making them a reasonable second-phase expansion target.
• Select an integrated representative with both registration capability and a nationwide distribution network, or deliberately separate registration (independent AR) from distribution (see Element 2) if certificate-continuity risk outweighs coordination convenience.
• If budget allows, register a Type B product alongside a Type C product in the same line to establish an earlier-revenue foothold while the higher-risk registration is still in process.

Key risks:

• Approval backlog and unpredictability: the post-COVID DAV/DMEC backlog has not fully cleared as of this verification round; all submissions require generous time buffers beyond the official targets.
• Policy and institutional-naming change risk: the transition from Decree 36/2016 to Decree 98/2021 previously created significant uncertainty for in-process applications, and this page identified unconfirmed signals of further institutional and procedural change in 2024–2026 (see Element 3) — future regulatory adjustments may again affect applications under review.
• Authentication-document expiry risk: notarized/authenticated documents typically carry a 6–12 month validity window; if review timelines extend (the norm, not the exception, for Type C/D), documents may expire and require costly re-authentication.
• AR registration-certificate lock-in risk: the certificate belongs to the AR; changing representatives requires a formal variation application — contracts must protect the manufacturer's data-package rights and transfer terms proactively, before signing.
• Local-testing-lab bottleneck: testing-lab scheduling queues (3–9 months) can become the last item on the critical path if not booked in parallel with DAV/DMEC submission.

Practical tips:

• Confirm the current submitting authority (DAV vs. DMEC), current regulation set, and current fee schedule directly with MOH or a local AR before committing to a submission strategy — this page's institutional-naming and fee figures carry unresolved uncertainty flagged throughout (Elements 3 and 5).
• Initiate the notarization/authentication chain and local-technical-testing booking at the same time as dossier preparation, not sequentially after it.
• The Vietnam Medical Device and Diagnostics Industry Association (VDCA) is a valuable platform for building local networks and staying current with policy developments.

Frequently Asked Questions

Who regulates medical devices in Vietnam?

The Ministry of Health (MOH) is Vietnam's national regulator for medical devices, operating under Decree No. 98/2021/ND-CP as amended by Decree No. 07/2023/ND-CP. Device-specific technical review has historically sat with the Department of Medical Equipment and Health Works (DMEC/DMEHW), with drug-adjacent coordination through DAV (Drug Administration of Vietnam) — the exact current institutional split could not be independently confirmed this round (see Regulatory Authority section), so confirm the correct submitting authority with MOH or a local representative before filing.

Does Vietnam require a mandatory local Authorized Representative?

Yes, without exception. A foreign manufacturer cannot register a device directly with DAV/DMEC. A Vietnam-established Authorized Representative, holding an MOH-issued medical-device business licence, must submit the application and typically holds the marketing-authorization certificate itself — see Element 2 for the control and speed trade-offs among an own-subsidiary AR, an independent third-party AR, and a distributor-held AR.

How long is a Vietnamese medical device registration valid?

Vietnam's Type B/C/D marketing-authorization certificate is documented as valid for 5 years under Decree 98/2021, consistent with the pattern across most of ASEAN. This page identified a single lower-confidence secondary source claiming this has changed to indefinite validity, but that claim could not be independently verified against a primary DAV/MOH source and is flagged 【待核验】rather than incorporated — confirm directly with MOH before a renewal-budget or submission-critical decision.

How long does Vietnamese registration actually take?

It depends heavily on classification. Type A notifications, requiring no substantive technical review, typically clear in ~2–6 weeks. Type B devices officially target 45 working days but typically take 9–18 months in practice. Type C devices officially target 60 working days but typically take 12–24 months. Type D devices officially target 90 working days but typically take 18–36+ months, with some complex products exceeding 3 years — driven primarily by the notarization/authentication chain, local-testing-lab queues, and supplementary-information rounds rather than the nominal review-day target.

Does an existing CE or FDA approval speed up Vietnamese registration?

Yes, but through a materially narrower mechanism than in Malaysia, Thailand, or Singapore. Vietnam has no formal, separate expedited-review or reliance route. A CE certificate or FDA clearance/approval is treated as core proof of overseas registration within the standard DAV/DMEC review, reducing deficiency/supplementary-information queries — and for Type D devices, FDA PMA clinical data can substitute for locally generated clinical evidence. Neither approval waives the local AR requirement, Vietnamese-language labelling, or (for Type C/D) local Vietnamese technical testing. China's NMPA is not recognized as a reference market.

Is there a formal fast-track pathway in Vietnam, like Malaysia's Verification Route or Thailand's Expedited Review?

No. This is one of the clearest differentiators of the Vietnamese system relative to its ASEAN neighbors: Vietnam does not operate a formally separate, faster procedural track tied to reference-country approval. Reference-country evidence reduces friction within the standard review rather than unlocking a different, faster one — see Element 8 and the Expedited Market Access section.

Are IVDs and SaMD registered differently from general medical devices?

IVDs follow a separate classification scheme based on the WHO IVD-classification framework but use the same notification/marketing-authorization mechanics as general devices. Whether specific high-risk IVD categories carry a Vietnam-specific local-testing requirement comparable to Thailand's HIV/COVID-19 test-kit rule could not be confirmed this round (【待核验】). SaMD is regulated under the same Type A–D framework as hardware, with IEC 62304-aligned software documentation expected for the dossier, and no separate SaMD-specific decree identified in this round's sources.

What is Vietnam's single biggest Vietnam-specific delay risk that CE/FDA evidence does not fix?

The notarization/authentication chain (2–4 months to prepare, with authenticated documents expiring after 6–12 months) and the local Vietnamese technical-testing requirement for Type C/D (3–9 months of lab-queue time) are both Vietnam-specific workstreams that exist independently of reference-country evidence quality — plan and book both in parallel with dossier preparation from the start of the project, not after submission.

Official Sources and Verification Dates

• Ministry of Health (MOH) medical device registration system: https://dichvucong.moh.gov.vn (MOH Public Services Portal; not independently fetched this round beyond confirming the URL from prior verified content)
• DAV (Drug Administration of Vietnam) official portal: https://dav.gov.vn (attempted fetch this round returned a connection error; content on this page could not be directly verified against this source)
• Department of Medical Equipment and Health Works (DMEC) portal, as referenced in this card's research brief: https://dmec.moh.gov.vn (attempted fetch this round returned a DNS resolution failure; domain could not be confirmed live)
• Local-representative and AR-structuring guidance (secondary, independently reviewed this round): https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/local-agent-representation/vietnam/ (accessed 2026-08-17) — corroborates DAV and the Department of Medical Equipment and Health Works (DMEHW) as the two relevant bodies, and the AR/certificate-holder-switching risk described in Element 2
• Southeast Asia regional market-entry comparison (same site, internal cross-check for consistency): src/shared/lib/southeast-asia-market-entry-topic.ts — Vietnam delta-table row (regulator: DAV; holder mode: Mode B; validity: 5 years; special requirement: notarization/authentication chain, mandatory Vietnamese labelling, Type C/D local testing)
• Vietnamese primary legal-database source attempted (blocked to direct fetch this round, HTTP 403): https://thuvienphapluat.vn — Decree 98/2021/ND-CP and Decree 07/2023/ND-CP full text could not be directly retrieved this round; decree numbers and general effect (transition-deadline extension) are cross-referenced across secondary regulatory-services sources instead
• Secondary regulatory-services sources reviewed but not incorporated due to unresolved reliability concerns (contradictory or uncorroborated claims — see Elements 3, 5, and 8 for the specific claims and reasoning): meddeviceguide.com (Vietnam medical device registration guide), pureglobal.com (Vietnam market page) — both accessed 2026-08-17
• Vietnam Medical Device and Diagnostics Industry Association (VDCA) — referenced as a local-network resource in prior verified content on this page
• Verification date: 2026-08-17

Items flagged for further verification (【待核验】)

• The exact current institutional split between DAV and the Department of Medical Equipment and Health Works (DMEC/DMEHW) for medical-device regulatory functions — both dav.gov.vn and dmec.moh.gov.vn were unreachable to direct fetch this round.
• Whether Vietnam's Type B/C/D marketing-authorization certificate validity has changed from 5 years to indefinite validity under a later amendment to Decree 98/2021 — one lower-confidence secondary source claimed this; not independently confirmed against a primary or second independently reliable source this round; this page keeps the 5-year figure, consistent with the Southeast Asia market-entry topic module.
• The exact article/provision number within Decree 98/2021 (or a successor instrument) governing reference-country/overseas-registration evidence for Type B/C/D dossiers — the functional mechanism is well corroborated across secondary sources, but the specific citation could not be verified against the primary decree text this round.
• Whether specific high-risk IVD categories (e.g., HIV/HBV/HCV screening) carry a Vietnam-specific mandatory local-testing requirement comparable to Thailand's HIV/COVID-19 test-kit rule.
• Whether a temporary ~50% reduction in MOH application fees, additional 2024–2026 amending decrees/circulars, or an agency-portal rename beyond Decree 07/2023 are genuine — two lower-confidence secondary sources referenced these claims with overlapping, hard-to-verify specifics (including an unconfirmed agency name); neither could be corroborated against a primary source this round.
• Whether a fixed expiry or periodic-reconfirmation requirement applies to the Type A notification itself, beyond the requirement to display the notification number on packaging.